Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;13(5):443-453.
doi: 10.2217/fon-2016-0253. Epub 2016 Nov 14.

Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?

Maria C Previdi  1 , Pietro Carotenuto  1 , Domenico Zito  1 , Rosantony Pandolfo  1 , Chiara Braconi  1   2
Affiliations
Review

Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know?

Maria C Previdi et al. Future Oncol. 2017 Feb.

Abstract

Pancreatic cancer is an aggressive cancer of the digestive system, which is becoming a serious health problem worldwide. Overall survival for patients with pancreatic cancer is poor, mainly due to a lack of biomarkers to enable early diagnosis and a lack of prognostic markers that can inform decision-making, facilitating personalized treatment and an optimal clinical outcome. ncRNAs play an important role in pancreatic carcinogenesis. Here we review the literature on the role of ncRNAs as biomarkers in pancreatic cancer. We focus on the significance of ncRNAs as markers for early diagnosis, as prognostic biomarkers able to inform clinical management and as targets for novel therapeutics for patients with pancreatic cancer.

Keywords: biomarker; lncRNA; miRNA; ncRNA; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests diclosure C Braconi is currently funded by an Institute of Cancer Research Clinician-Scientist Fellowship, a Marie Curie Career Integration Grant (EU), a Research Innovation Fund by Pancreatic Cancer UK, an Early Diagnosis Challenge Award from Pancreatic Cancer Action and a project grant from NIHR/BRC at the Royal Marsden/Institute of Cancer Research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66(1):7–30. - PubMed
    1. Conroy T, Bachet JB, Ayav A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur. J. Cancer. 2016;57:10–22. - PubMed
    1. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 2011;17(4):500–503. - PMC - PubMed
    1. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. - PubMed
    1. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501. - PMC - PubMed

LinkOut - more resources